NCT06293417View on ClinicalTrials.gov

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

NARecruitingINTERVENTIONAL
Enrollment

3,958

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
T2DM (Type 2 Diabetes Mellitus)Dyslipidemias
Interventions
DRUG

Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

Treatment group

DRUG

Dose escalation of moderate-intensity statin

Control group

Trial Locations (1)

Unknown

RECRUITING

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Korea University Anam Hospital

OTHER